Anticipated therapeutic concentrations of ESBATech’s antibody fragments were observed in the anterior chamber (front of the eye) and in the posterior segments (back of the eye) including vitreous humour, retina, and choroid. ESBATech’s lead antibody fragment ESBA105 is a TNFa antagonist that is scheduled to enter clinical development later in 2008.
Dominik Escher, CEO of ESBATech, said: “We believe that with our highly stable and monomeric single-chain antibody fragments, we now meet the protein requirements that allow for sufficient delivery of immune binders into all segments of the eye via eye drops.”